The HSD17B10 antibody is a crucial tool for studying the multifunctional mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (HSD17B10), also known as ERAB, ABAD, or MHBD. This protein plays diverse roles in steroid metabolism, neuroprotection, and mitochondrial function. It catalyzes the oxidation of steroids, including the conversion of estradiol to estrone, and participates in the catabolism of branched-chain amino acids and fatty acids. HSD17B10 is implicated in neurological disorders, particularly Alzheimer’s disease, as it interacts with amyloid-β peptide, potentially contributing to neuronal toxicity. Additionally, mutations in the HSD17B10 gene are linked to HSD10 disease, a rare X-linked neurodevelopmental disorder characterized by intellectual disability, seizures, and cardiomyopathy.
The HSD17B10 antibody enables researchers to detect and quantify this protein in various experimental settings, such as Western blotting, immunohistochemistry, and immunofluorescence. Its application aids in understanding tissue-specific expression, subcellular localization, and altered expression patterns in disease models. Validated antibodies are essential for distinguishing HSD17B10 from structurally similar enzymes, ensuring specificity in studies exploring its dual roles in metabolism and neurodegeneration. Both monoclonal and polyclonal variants are available, with selection depending on assay requirements. Researchers often use knockout controls or peptide blocking to confirm antibody specificity. Overall, the HSD17B10 antibody is vital for elucidating the protein’s pathophysiological mechanisms and potential therapeutic targets.